7-Nov-2024
No headlines found.
Accolade Welcomes Renalogic to Trusted Partner Ecosystem
PRNewswire (Tue, 15-Oct 9:00 AM ET)
Accolade Announces Results for Fiscal Second Quarter 2025
Globe Newswire (Tue, 8-Oct 7:00 AM ET)
Accolade to Announce Fiscal Second Quarter 2025 Financial Results
Globe Newswire (Wed, 18-Sep 8:00 AM ET)
Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Globe Newswire (Wed, 28-Aug 8:00 AM ET)
First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies
PRNewswire (Thu, 22-Aug 10:03 AM ET)
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Accolade trades on the NASDAQ stock market under the symbol ACCD.
As of November 7, 2024, ACCD stock price climbed to $3.56 with 1,407,207 million shares trading.
ACCD has a beta of 1.77, meaning it tends to be more sensitive to market movements. ACCD has a correlation of 0.07 to the broad based SPY ETF.
ACCD has a market cap of $286.71 million. This is considered a Small Cap stock.
Last quarter Accolade reported $106 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.14.
In the last 3 years, ACCD traded as high as $40.49 and as low as $3.08.
The top ETF exchange traded funds that ACCD belongs to (by Net Assets): ARKG, VTI, IWM, VXF, IWN.
ACCD has underperformed the market in the last year with a return of -49.6%, while the SPY ETF gained +38.3%. In the last 3 month period, ACCD fell short of the market, returning -0.6%, while SPY returned +14.4%. However, in the most recent 2 weeks ACCD has outperformed the stock market by returning +11.3%, while SPY returned +3.0%.
ACCD support price is $3.29 and resistance is $3.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACCD shares will trade within this expected range on the day.